{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T01:58:41Z","timestamp":1789178321637,"version":"build-2803163510"},"reference-count":44,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,22]],"date-time":"2024-12-22T00:00:00Z","timestamp":1734825600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.clml.2024.11.014","type":"journal-article","created":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T15:04:13Z","timestamp":1734361453000},"page":"e183-e199.e8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Real-World Effectiveness of Chemoimmunotherapy and Novel Therapies for Patients With Relapsed\/Refractory Aggressive Large B-Cell Lymphoma"],"prefix":"10.1016","volume":"25","author":[{"given":"Loretta J.","family":"Nastoupil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1846-9117","authenticated-orcid":false,"given":"Clark R.","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Ayers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1576-8341","authenticated-orcid":false,"given":"Yucai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas M.","family":"Habermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dai","family":"Chihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0459-6609","authenticated-orcid":false,"given":"Brad S.","family":"Kahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5084-0698","authenticated-orcid":false,"given":"Brian K.","family":"Link","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean L.","family":"Koff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathon B.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izidore S.","family":"Lossos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4691-7645","authenticated-orcid":false,"given":"Michele","family":"Stanchina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Haddadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Casulo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabarish","family":"Ayyappan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruitao","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8359-0533","authenticated-orcid":false,"given":"Ziyi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa A.","family":"Larson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1867-0526","authenticated-orcid":false,"given":"Matthew J.","family":"Maurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn","family":"Huynh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8029-4496","authenticated-orcid":false,"given":"Chi","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramya","family":"Ramasubramanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei Sheng","family":"Duh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Mutebi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tongsheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Jun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7551-4730","authenticated-orcid":false,"given":"Anthony","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh","family":"Kamalakar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anupama","family":"Kalsekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7482-178X","authenticated-orcid":false,"given":"James R.","family":"Cerhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9524-3990","authenticated-orcid":false,"given":"Christopher R.","family":"Flowers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2024.11.014_bib0001","unstructured":"Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia. ;36(7):1720-1748. https:\/\/www.nature.com\/articles\/s41375-022-01620-2"},{"issue":"4","key":"10.1016\/j.clml.2024.11.014_bib0002","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2024.11.014_bib0003","unstructured":"Two New Indications Approved for Rituximab in NHL. The cancer network; November 1, 2006 (Oncology, Volume 20, Issue 12). Available from: https:\/\/www.cancernetwork.com\/view\/two-new-indications-approved-rituximab-nhl. Accessed February 23, 2024."},{"issue":"16","key":"10.1016\/j.clml.2024.11.014_bib0004","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.clml.2024.11.014_bib0005","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","article-title":"Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma","volume":"333","author":"Philip","year":"1995","journal-title":"N Engl J Med"},{"issue":"27","key":"10.1016\/j.clml.2024.11.014_bib0006","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","article-title":"Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era","volume":"28","author":"Gisselbrecht","year":"2010","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.clml.2024.11.014_bib0007","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1200\/JCO.2016.69.0198","article-title":"Ofatumumab versus rituximab salvage chemoimmunotherapy in relapsed or refractory diffuse large B-cell lymphoma: the ORCHARRD study","volume":"35","author":"van Imhoff","year":"2017","journal-title":"J Clin Oncol"},{"issue":"26","key":"10.1016\/j.clml.2024.11.014_bib0008","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.clml.2024.11.014_bib0009","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"issue":"10254","key":"10.1016\/j.clml.2024.11.014_bib0010","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"issue":"10343","key":"10.1016\/j.clml.2024.11.014_bib0011","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","volume":"399","author":"Kamdar","year":"2022","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.clml.2024.11.014_bib0012","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1056\/NEJMoa2301665","article-title":"Survival with axicabtagene ciloleucel in large B-cell lymphoma","volume":"389","author":"Westin","year":"2023","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.clml.2024.11.014_bib0013","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1182\/hematology.2023000518","article-title":"Barriers to accessing cellular therapy for patients receiving care in community practices","volume":"2023","author":"Nze","year":"2023","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"12","key":"10.1016\/j.clml.2024.11.014_bib0014","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1182\/blood.2023020197","article-title":"Real-world experience of CAR T-cell therapy in older patients with relapsed\/refractory diffuse large B-cell lymphoma","volume":"142","author":"Chihara","year":"2023","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.clml.2024.11.014_bib0015","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/S1470-2045(20)30225-4","article-title":"Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study","volume":"21","author":"Salles","year":"2020","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.clml.2024.11.014_bib0016","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/S1470-2045(21)00139-X","article-title":"Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial","volume":"22","author":"Caimi","year":"2021","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.clml.2024.11.014_bib0017","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1200\/JCO.19.00172","article-title":"Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma","volume":"38","author":"Sehn","year":"2020","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.clml.2024.11.014_bib0018","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1200\/JCO.22.01725","article-title":"Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I\/II trial","volume":"41","author":"Thieblemont","year":"2023","journal-title":"J Clin Oncol"},{"issue":"24","key":"10.1016\/j.clml.2024.11.014_bib0019","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","article-title":"Glofitamab for relapsed or refractory diffuse large B-cell lymphoma","volume":"387","author":"Dickinson","year":"2022","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.clml.2024.11.014_bib0020","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.clml.2024.11.014_bib0021","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa2116596","article-title":"Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma","volume":"386","author":"Bishop","year":"2022","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.clml.2024.11.014_bib0022","doi-asserted-by":"crossref","first-page":"e373","DOI":"10.1016\/j.clml.2020.11.008","article-title":"Outcomes of transplant-eligible patients with relapsed or refractory diffuse large B-cell lymphoma after second-line salvage chemotherapy: the Gustave Roussy experience","volume":"21","author":"Rassy","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"2","key":"10.1016\/j.clml.2024.11.014_bib0023","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/bmt.2016.213","article-title":"Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study","volume":"52","author":"Van Den Neste","year":"2017","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1016\/j.clml.2024.11.014_bib0024","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/cncr.32526","article-title":"Outcomes in patients with aggressive B-cell non-Hodgkin lymphoma after intensive frontline treatment failure","volume":"126","author":"Ayers","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2024.11.014_bib0025","doi-asserted-by":"crossref","first-page":"2904","DOI":"10.1182\/blood-2019-122760","article-title":"Retrospective analysis of gemcitabine and oxaliplatin (GemOx)-based treatment in patients with relapsed\/refractory aggressive B-cell non-Hodgkin lymphoma","volume":"134","author":"Schade","year":"2019","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.clml.2024.11.014_bib0026","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1080\/10428194.2021.1901090","article-title":"Rituximab plus gemcitabine and oxaliplatin (R-GemOx) in refractory\/relapsed diffuse large B-cell lymphoma: a real-life study in patients ineligible for autologous stem-cell transplantation","volume":"62","author":"Cazelles","year":"2021","journal-title":"Leuk Lymphoma"},{"issue":"17","key":"10.1016\/j.clml.2024.11.014_bib0027","doi-asserted-by":"crossref","first-page":"17808","DOI":"10.1002\/cam4.6412","article-title":"Clinical outcomes in transplant-eligible patients with relapsed or refractory diffuse large B-cell lymphoma after second-line salvage chemotherapy: a retrospective study","volume":"12","author":"Yagi","year":"2023","journal-title":"Cancer Med"},{"issue":"1","key":"10.1016\/j.clml.2024.11.014_bib0028","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/bmt.2015.213","article-title":"Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the international CORAL study","volume":"51","author":"Van Den Neste","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1016\/j.clml.2024.11.014_bib46","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1182\/bloodadvances.2021005794","article-title":"Polatuzumab vedotin plus bendamustine and rituximab in relapsed\/refractory DLBCL: survival update and new extension cohort data","volume":"6","author":"Sehn","year":"2022","journal-title":"Blood Adv"},{"issue":"9","key":"10.1016\/j.clml.2024.11.014_bib0029","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.3324\/haematol.2020.275958","article-title":"Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma","volume":"106","author":"Duell","year":"2021","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.clml.2024.11.014_sbref0030","first-page":"1184","article-title":"Loncastuximab tesirine in relapsed\/refractory diffuse large B-cell lymphoma: long-term efficacy and safety from the phase II LOTIS-2 study","volume":"109","author":"Caimi","year":"2024","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2024.11.014_bib0034","series-title":"Real-World Outcomes With Novel Therapies in RIR DLBCL","year":"2023"},{"issue":"7","key":"10.1016\/j.clml.2024.11.014_bib0032","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1007\/s00277-023-05196-4","volume":"102","author":"Nowakowski","year":"2023","journal-title":"Ann Hematol"},{"issue":"3","key":"10.1016\/j.clml.2024.11.014_bib0033","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.clml.2020.12.013","article-title":"Polatuzumab vedotin for relapsed\/refractory aggressive B-cell lymphoma: a multicenter post-marketing analysis","volume":"21","author":"Smith","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2024.11.014_bib0035","doi-asserted-by":"crossref","first-page":"8058","DOI":"10.1182\/blood-2022-167753","article-title":"Real-world outcomes in relapsed\/refractory DLBCL patients who received polatuzumab vedotin PLUS bendamustine and rituximab or tafasitamab plus lenalidomide by line of therapy","volume":"140","author":"Hamadani","year":"2022","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.clml.2024.11.014_bib0036","doi-asserted-by":"crossref","first-page":"e798","DOI":"10.1097\/HS9.0000000000000798","article-title":"Real-world outcomes of relapsed\/refractory diffuse large B-cell lymphoma treated with polatuzumab vedotin-based therapy","volume":"6","author":"Argnani","year":"2022","journal-title":"Hemasphere"},{"issue":"3","key":"10.1016\/j.clml.2024.11.014_bib0037","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/hon.2842","article-title":"Real-life experience with the combination of polatuzumab vedotin, rituximab, and bendamustine in aggressive B-cell lymphomas","volume":"39","author":"Dimou","year":"2021","journal-title":"Hematol Oncol"},{"issue":"19","key":"10.1016\/j.clml.2024.11.014_bib0038","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.21037\/atm-22-4593","article-title":"A retrospective cohort study of polatuzumab vedotin combined with immunochemotherapy in Chinese patients with relapse\/refractory diffuse large B cell lymphoma","volume":"10","author":"Liu","year":"2022","journal-title":"Ann Transl Med"},{"issue":"9","key":"10.1016\/j.clml.2024.11.014_bib0039","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1182\/bloodadvances.2021005953","article-title":"Results of a United Kingdom real-world study of polatuzumab vedotin, bendamustine, and rituximab for relapsed\/refractory DLBCL","volume":"6","author":"Northend","year":"2022","journal-title":"Blood Adv"},{"issue":"7","key":"10.1016\/j.clml.2024.11.014_bib0040","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1007\/s00277-023-05273-8","article-title":"Outcomes of polatuzumab vedotin-containing regimens in real-world setting of relapsed and or refractory diffuse large B-cell lymphoma patients: a matched-control analysis from the Thai Lymphoma Study Group (TLSG)","volume":"102","author":"Rattanathammethee","year":"2023","journal-title":"Ann Hematol"},{"issue":"9","key":"10.1016\/j.clml.2024.11.014_bib0042","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1182\/bloodadvances.2021006801","article-title":"A multicenter retrospective study of polatuzumab vedotin in patients with large B-cell lymphoma after CAR T-cell therapy","volume":"6","author":"Gouni","year":"2022","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.clml.2024.11.014_bib0043","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.4143\/crt.2022.1658","article-title":"Efficacy of salvage treatments in relapsed or refractory diffuse large B-cell lymphoma including chimeric antigen receptor T-cell therapy: a systematic review and meta-analysis","volume":"55","author":"Kim","year":"2023","journal-title":"Cancer Res Treat"},{"issue":"1","key":"10.1016\/j.clml.2024.11.014_bib0044","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1182\/hematology.2022000332","article-title":"Sequencing therapy in relapsed DLBCL","volume":"2022","author":"Flowers","year":"2022","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"5","key":"10.1016\/j.clml.2024.11.014_bib0045","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1002\/ajh.26149","article-title":"Relapsed\/refractory international prognostic index (R\/R-IPI): an international prognostic calculator for relapsed\/refractory diffuse large B-cell lymphoma","volume":"96","author":"Maurer","year":"2021","journal-title":"Am J Hematol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024024376?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024024376?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T06:39:04Z","timestamp":1772606344000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265024024376"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":44,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S2152265024024376"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2024.11.014","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-World Effectiveness of Chemoimmunotherapy and Novel Therapies for Patients With Relapsed\/Refractory Aggressive Large B-Cell Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2024.11.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}